Outcome Prediction Using Radiomics for Irinotecan-TACE in Colorectal Liver Metastases: Insights from the Prospective CIREL Study - Takeaways - MDSpire

Outcome Prediction Using Radiomics for Irinotecan-TACE in Colorectal Liver Metastases: Insights from the Prospective CIREL Study

  • By

  • Zuhir Bodalal

  • Francisco Javier Mendoza Ferradás

  • Olga Maxouri

  • Roberto Iezzi

  • Aleksandar Gjoreski

  • Stavros Spiliopoulos

  • Zoltan Bansaghi

  • Belarmino Gonçalves

  • Bleranda Zeka

  • Nathalie Kaufmann

  • Julien Taieb

  • Regina Beets-Tan

  • Philippe L. Pereira

  • Fernando Gómez Muñoz

  • April 29, 2026

  • 0 min

Share

  • 1

    Colorectal liver metastases (CRLMs) affect up to 25% of patients at diagnosis, with many developing hepatic metastases within two years.

  • 2

    Irinotecan-TACE offers targeted delivery of chemotherapy to liver tumors, potentially improving outcomes while minimizing systemic side effects.

  • 3

    The CIREL study aims to gather real-world data on irinotecan-TACE effectiveness and identify optimal patient selection for this treatment.

  • 4

    Radiomics utilizes advanced imaging analysis to extract features that may enhance prediction of treatment outcomes in CRLM patients.

  • 5

    This study focuses on developing machine learning models to predict overall survival and treatment response in patients receiving irinotecan-TACE.

Original Source(s)

Related Content